TD Cowen initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note released on ...

I will describe four of the 10 new flowers that have received awards from All-America Selections, the nonprofit testing ...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.

TD Cowen initiated coverage of Dianthus (DNTH) with a Buy rating and no price target The firm says DNTH103 is “highly potent” and selectively ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $47.2, a ...

State Street Corp grew its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) by 101.4% during the ...

A unique fjord in Chilean Patagonia gives scientists a chance to unlock the reproductive secrets of cold-water corals that ...

Dianthus Therapeutics (DNTH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami ...

Dianthus Therapeutics (DNTH – Research Report) received a Buy rating and price target from TD Cowen analyst Yaron Werber today. The company’s ...

I will describe four of the 10 new flowers that have received awards from All-America Selections, the nonprofit testing ...

周五，TD Cowen对Dianthus Therapeutics (NASDAQ:DNTH)启动了覆盖，给予这家生物制药公司的股票买入评级。该公司加入了强烈看好的分析师阵营，分析师们给出的目标价范围从36美元到84美元不等。

Dianthus Therapeutics (NASDAQ:DNTH) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview ...